Hematology-Oncology
Latest news
316 articles · 20 / page
Tandem CD19/CD22 CAR T-Cell Therapy: A Promising Advance for High-Risk Pediatric and AYA r/r B-ALL
Tandem CD19/CD22 CAR T-cell therapy shows encouraging safety and efficacy in heavily pretreated children and young adults with relapsed/refractory B-ALL, particularly when combined with consolidative hematopoietic stem cell transplantation.
Proinflammatory Cytokines and Low Peripheral Blood Counts Predict Poor Outcomes after CD19 CAR-T Therapy in Acute Lymphoblastic Leukemia
Elevated proinflammatory cytokines combined with low peripheral blood counts early after CD19 CAR-T cell infusion correlate with poor treatment response and severe toxicity in relapsed/refractory B-ALL, highlighting inflammation as a key mo
T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance
A novel grading system, T-ICAHT, quantifies thrombocytopenia after CAR T-cell therapy, revealing its prevalence and prognostic impact, highlighting its value in patient management and outcome prediction across hematologic malignancies.
ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia
The ZUMA-8 phase 1 study evaluates the safety and efficacy of brexucabtagene autoleucel, a CD19-directed CAR T-cell therapy, in relapsed/refractory CLL, showing promising response rates and manageable safety profiles, especially in patients
Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study
This phase 2 trial evaluated modakafusp alfa, a novel immunocytokine targeting CD38+ cells, in heavily pretreated relapsed/refractory multiple myeloma, showing promising efficacy and manageable toxicity despite early termination.
Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML
The phase 2 AUGMENT-101 study demonstrates that revumenib, a selective menin inhibitor, induces meaningful remissions and enables stem cell transplantation in heavily pretreated, older patients with relapsed or refractory NPM1-mutated AML,
Pemigatinib: A Breakthrough Targeted Therapy for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements
Pemigatinib demonstrates high efficacy and manageable toxicity in treating MLN-FGFR1, especially in chronic-phase patients, addressing a critical unmet need in this aggressive neoplasm.
Venous Thromboembolism in Newly Diagnosed Lymphoma Patients: Insights from a Real-World Vietnamese Cohort
An 8.3% incidence of VTE was observed in newly diagnosed lymphoma patients in Vietnam, with pretreatment elevated D-dimer and cardiovascular comorbidities as key risk factors, emphasizing the need for tailored thromboprophylaxis.
Linperlisib Plus Chidamide: A Promising Oral Therapy for Relapsed or Refractory Cutaneous T-Cell Lymphoma
This phase 1 trial demonstrates that linperlisib combined with chidamide offers manageable safety and noteworthy efficacy in relapsed or refractory cutaneous T-cell lymphoma, providing a potential new all-oral therapeutic option for advance
Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up
Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell ly
Can Eltrombopag Transform Aplastic Anemia Care?
Eltrombopag combined with immunosuppressive therapy shows promising efficacy in severe aplastic anemia, especially in relapsed/refractory pediatric patients, with over half achieving hematologic responses and transfusion independence, suppo
Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial
The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.
Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA
Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.
Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial
Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.
Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.
Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side
Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial
KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.
Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial
A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this po
Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial
The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic
Browse by specialty
Open language-specific specialty feeds and department pages.